Latham advised Leonard Green & Partners in the €64 million Series B financing round of TreeFrog Therapeutics.

Latham advised Leonard Green & Partners in the €64 million Series B financing round of TreeFrog Therapeutics, a company specializing stem cell-derived cell therapies. The Series B financing round was led by Bpifrance Large Venture, joined by U.S. investment firm Leonard Green & Partners L.P. and the global pharmaceutical company Bristol-Myers Squibb.

Latham is advising Leonard Green & Partners with a corporate team led by New York partner Howard A. Sobel and Los Angeles partner David Ajalat, with Paris associate Simon Lange.